Humacyte, Inc. (HUMA)
| Previous Close | 4.9300 |
| Open | 4.9300 |
| Bid | 4.9800 x 100 |
| Ask | 5.0100 x 400 |
| Day's Range | 4.8500 - 5.1050 |
| 52 Week Range | 1.9600 - 9.9700 |
| Volume | |
| Avg. Volume | 2,367,309 |
| Market Cap | 594.229M |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0000 |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.25 |
GlobeNewswireHumacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
– BioVascular Pancreas (BVP) product candidate is under development as a potential treatment for type 1 diabetes – – Humacyte’s stem cell-derived islets observed to restore normal blood glucose in diabetic mice – – Non-human primate models of BVP implantation showed islet survival and continued insulin production – DURHAM, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human
- GlobeNewswire
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinical trial results and real-world use treating wartime trauma injuries in Ukraine – DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantabl
Simply Wall St.This Is Why Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Looks Appropriate
Key Insights Humacyte to hold its Annual General Meeting on 11th of June Salary of US$603.8k is part of CEO Laura...
